VECTIBIX 400MG/20ML VIAL

PHARMACOLOGY RECOMBINANT HUMAN IGG2 MONOCLONAL ANTIBODY WHICH BINDS SPECIFICALLY TO THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR HER1 C-ERBB-1) AND COMPETITIVELY INHIBITS THE BINDING OF EPIDERMAL GROWTH FACTOR (EGF) AND OTHER LIGANDS. USE: LABELED INDICATIONS COLORECTAL CANCER METASTATIC: TREATMENT OF PATIENTS WITH WILD-TYPE KRAS (EXON 2 IN CODONS 12 OR 13) METASTATIC COLORECTAL CANCER (MCRC) EITHER AS FIRST-LINE THERAPY IN COMBINATION WITH FOLFOX (FLUOROURACIL LEUCOVORIN AND OXALIPLATIN) OR AS A SINGLE AGENT FOLLOWING DISEASE PROGRESSION AFTER PRIOR TREATMENT WITH FLUOROPYRIMIDINE- OXALIPLATIN- AND IRINOTECAN-CONTAINING CHEMOTHERAPY REGIMENS LIMITATIONS OF USE: PANITUMUMAB IS NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH RAS-MUTANT MCRC OR FOR WHOM RAS MUTATION STATUS IS UNKNOWN.